) The purpose of this Clinical Oncology Research Career Development Program is to ensure career development of clinical investigators who can conduct innovative hypothesis-driven research in the clinic and community. In an era when advances in the laboratory are accelerating more rapidly than advances in the clinic, successful clinical investigators must not only conduct clinical trials, but also understand and utilize new biology to develop innovative strategies for cancer treatment, detection and prevention. Thus, successful clinical investigators must be able to collaborate with colleagues in the laboratory and in other clinical disciplines, as well as in the public and private sectors. Awardees must have a junior faculty position and be board-certified or board-eligible in any of the clinical oncology disciplines, including surgical, gynecologic, medical, pediatric, or radiation oncology. Individuals who have excelled in their clinical training and have a clear commitment to academic oncology, as evidenced by previous publications and a credible plan for career development, will be considered. Particular attention will be given to recruitment of talented investigators of both genders and of under-represented ethnic groups. Training activities will include participation in the curriculum provided by a K30 Clinical Research Curriculum award and additional course work, generally leading to an M.S. degree in clinical investigation or an M.P.H. degree in community-based research. Opportunities will be provided for externships at FDA and leading biopharmaceutical companies. Each trainee will complete multiple projects mentored by one or more senior faculty with a track record for conducting hypothesis-driven clinical or community-based research with a strong translational component, often in collaboration with investigators from other disciplines. Each trainee will be expected to publish multiple papers in respected journals and attain peer-reviewed funding. Awardees will be supported for two to five years with annual renewal based on progress toward defined goals. Dr. Robert Bast will lead the overall program in collaboration with Dr. James Cox (clinical investigation) and Dr. Robert Chamberlain (community-based research). An Advisory Committee of senior leaders in the relevant clinical disciplines will advise the Program Leader on all matters of policy, select awardees, and monitor their progress. Support is requested for 4 junior faculty clinical oncologists annually.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA088084-05
Application #
6804068
Study Section
Special Emphasis Panel (ZCA1-GRB-N (M1))
Program Officer
Lei, Ming
Project Start
2000-09-13
Project End
2005-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$538,920
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ikoma, Naruhiko; Das, Prajnan; Hofstetter, Wayne et al. (2018) Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 21:1004-1013
Raghavendra, Akshara; Sinha, Arup K; Valle-Goffin, Janeiro et al. (2018) Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors. Clin Breast Cancer 18:e7-e13
Keung, Emily Z; Lazar, Alexander J; Torres, Keila E et al. (2018) Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18:913
Livingston, J Andrew; Wang, Wei-Lien; Tsai, Jen-Wei et al. (2018) Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Mol Cancer Ther 17:1315-1323
Rosenberg, Abby R; Bradford, Miranda C; McCauley, Elizabeth et al. (2018) Promoting resilience in adolescents and young adults with cancer: Results from the PRISM randomized controlled trial. Cancer 124:3909-3917
Sahin, Ismet; Zhang, Yu; McAllister, Florencia (2018) Tumor Spheres Quantification with Smoothed Euclidean Distance Transform. J Mol Imaging Dyn 8:
MD Anderson Head and Neck Cancer Symptom Working Group; Kamal, Mona; Rosenthal, David I et al. (2018) Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiother Oncol 126:75-80
Bannon, Sarah A; Montiel, Maria F; Goldstein, Jennifer B et al. (2018) High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prev Res (Phila) 11:679-686
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008
Zhang, Hua; Sturgis, Erich; Zhu, Lijun et al. (2018) The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy. Transl Oncol 11:633-638

Showing the most recent 10 out of 210 publications